Llusern Scientific
Llusern Scientific is dedicated to developing innovative molecular diagnostic solutions to improve patient care and combat antimicrobial resistance. Their flagship product, Lodestar DX, provides rapid, accurate point-of-care testing for urinary tract infections in both human and veterinary medicine, enabling faster treatment decisions and reducing unnecessary antibiotic use. The company is actively involved in clinical verification, validation, and is recognized by NICE for its potential to improve antimicrobial prescribing. Llusern has received awards such as the Wales STEM Innovation Award and the Partnership with the NHS Award at MediWales, and has been featured in media including BBC Radio 4’s Woman’s Hour.
Industries
Nr. of Employees
small (1-50)
Llusern Scientific
Llusern Scientific Ltd, Cardiff Edge Business Park, Longwood Drive, Cardiff, CF14 7YU
Products
Portable LAMP-based point-of-care molecular analyser
Compact analyser and consumable test-panel system using isothermal amplification to detect multiple uropathogens from low-volume urine with ~35-minute run time, LED result indicators and Bluetooth/USB connectivity; designed for human and veterinary near-patient use and compatible with low-voltage/battery operation.
Portable LAMP-based point-of-care molecular analyser
Compact analyser and consumable test-panel system using isothermal amplification to detect multiple uropathogens from low-volume urine with ~35-minute run time, LED result indicators and Bluetooth/USB connectivity; designed for human and veterinary near-patient use and compatible with low-voltage/battery operation.
Services
Collaborative integration of third-party isothermal assays with a portable reader platform, including licensing and bespoke assay/sample design.
Support for clinical verification and validation studies of near-patient molecular diagnostics, including collaborations with healthcare organisations and publication of results.
Production of diagnostic assay kits and test panels within a quality management system aligned to ISO 13485 standards.
Product demonstrations and basic training for professional users on running near-patient molecular tests and interpreting LED-based results.
Support and participation in early value assessments and interactions with health technology assessment agencies to inform adoption decisions.
Implementation support and pilots in care settings to demonstrate impact of point-of-care testing on antibiotic prescribing.
Collaborative integration of third-party isothermal assays with a portable reader platform, including licensing and bespoke assay/sample design.
Support for clinical verification and validation studies of near-patient molecular diagnostics, including collaborations with healthcare organisations and publication of results.
Production of diagnostic assay kits and test panels within a quality management system aligned to ISO 13485 standards.
Product demonstrations and basic training for professional users on running near-patient molecular tests and interpreting LED-based results.
Support and participation in early value assessments and interactions with health technology assessment agencies to inform adoption decisions.
Implementation support and pilots in care settings to demonstrate impact of point-of-care testing on antibiotic prescribing.
Expertise Areas
- Point-of-care molecular diagnostics
- Urinary tract infection diagnostics
- Isothermal amplification assay development (LAMP)
- Clinical evaluation and validation of diagnostic tests
Key Technologies
- Loop-mediated isothermal amplification (LAMP)
- Multiplexed small-volume reaction panels
- Extraction-free urine sample processing
- Portable point-of-care molecular analyser hardware
News & Updates
Llusern Scientific reports on the positive impact of Lodestar DX in reducing antibiotic prescriptions in an elderly care setting.
The company has achieved ISO 13485 certification for its point-of-care diagnostics system for UTIs.
The company participated in Arab Health 2025, showcasing its innovative diagnostic platform.
Research demonstrating the effectiveness of Lodestar DX in complex clinical samples.
The company announced the start of its Series A investment round at BioSeed 2025.
David Browning, with 40 years of life-science experience, has been appointed as non-executive Chairman.
Llusern Scientific reports on the positive impact of Lodestar DX in reducing antibiotic prescriptions in an elderly care setting.
The company has achieved ISO 13485 certification for its point-of-care diagnostics system for UTIs.
The company participated in Arab Health 2025, showcasing its innovative diagnostic platform.
Research demonstrating the effectiveness of Lodestar DX in complex clinical samples.
The company announced the start of its Series A investment round at BioSeed 2025.
David Browning, with 40 years of life-science experience, has been appointed as non-executive Chairman.